In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $2.92 down -2.34% from its previous closing price of $2.99. In other words, the price has decreased by -$2.34 from its previous closing price. On the day, 0.31 million shares were traded. VYGR stock price reached its highest trading level at $2.97 during the session, while it also had its lowest trading level at $2.865.
Ratios:
For a deeper understanding of Voyager Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’25 when Ferguson Toby sold 10,086 shares for $3.43 per share. The transaction valued at 34,595 led to the insider holds 157,914 shares of the business.
Sandrock Alfred sold 10,885 shares of VYGR for $37,336 on Apr 02 ’25. The President and CEO now owns 430,931 shares after completing the transaction at $3.43 per share. On Apr 02 ’25, another insider, Sandrock Alfred, who serves as the Officer of the company, bought 10,885 shares for $3.43 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 161582288 and an Enterprise Value of -32440578. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.41 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at -0.484 whereas that against EBITDA is 0.343.
Stock Price History:
The Beta on a monthly basis for VYGR is 0.87, which has changed by -0.63545567 over the last 52 weeks, in comparison to a change of 0.09362543 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $9.55, while it has fallen to a 52-week low of $2.75. The 50-Day Moving Average of the stock is -14.25%, while the 200-Day Moving Average is calculated to be -44.97%.
Shares Statistics:
For the past three months, VYGR has traded an average of 358.09K shares per day and 373430 over the past ten days. A total of 55.21M shares are outstanding, with a floating share count of 45.00M. Insiders hold about 18.69% of the company’s shares, while institutions hold 62.85% stake in the company. Shares short for VYGR as of 1745971200 were 2896692 with a Short Ratio of 8.09, compared to 1743379200 on 2934642. Therefore, it implies a Short% of Shares Outstanding of 2896692 and a Short% of Float of 6.25.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 11.0 analysts are actively evaluating the performance of Voyager Therapeutics Inc (VYGR) in the stock market.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.33 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$1.58 and -$2.95 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$1.62, with 11.0 analysts recommending between -$0.39 and -$2.91.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $9.5M this quarter.It ranges from a high estimate of $20M to a low estimate of $1M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $29.58MFor the next quarter, 12 analysts are estimating revenue of $9.41M. There is a high estimate of $16.74M for the next quarter, whereas the lowest estimate is $1M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $63.75M, while the lowest revenue estimate was $9.47M, resulting in an average revenue estimate of $37.07M. In the same quarter a year ago, actual revenue was $80MBased on 11 analysts’ estimates, the company’s revenue will be $70.02M in the next fiscal year. The high estimate is $159.95M and the low estimate is $20M.
